Sen. Susan Collins (R-ME) tells Inside Drug Pricing that passing legislation to cap monthly insulin costs at $35 in the commercial market is one of her top priorities for the remainder of the 117th Congress. It remains unclear, however, whether the bill could make it into Congress’ expected year-end spending package. Collins said the recent announcements that UnitedHealth will provide insulin at no out-of-pocket cost and that BlueCross BlueShield will partner with Civica to provide $30 insulin show long-standing...